{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T12:38:20Z","timestamp":1785587900392,"version":"3.56.0"},"reference-count":16,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T00:00:00Z","timestamp":1492646400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR000117"],"award-info":[{"award-number":["UL1TR000117"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR001998"],"award-info":[{"award-number":["UL1TR001998"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2017,5]]},"abstract":"\n Study Objective<\/jats:title>\n \n Increased acute kidney injury (\n AKI<\/jats:styled-content>\n ) incidence has been reported in patients receiving piperacillin\u2010tazobactam (\n PTZ<\/jats:styled-content>\n ) therapy compared with other \u03b2\u2010lactams. The authors sought to determine if the addition of \u03b2\u2010lactamase inhibitors impacts\n AKI<\/jats:styled-content>\n incidence by comparing patients treated with\n PTZ<\/jats:styled-content>\n or ampicillin\u2010sulbactam (\n SAM<\/jats:styled-content>\n ).\n <\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n Retrospective cohort study.<\/jats:p>\n <\/jats:sec>\n \n Setting<\/jats:title>\n Large academic tertiary care hospital.<\/jats:p>\n <\/jats:sec>\n \n Patients<\/jats:title>\n \n Overall, 2448 patients received\n PTZ<\/jats:styled-content>\n (n=1836) or\n SAM<\/jats:styled-content>\n (n=612) for at least 48 hours between September 1, 2007, and September 30, 2015. Patients were excluded for pregnancy, cystic fibrosis, chronic kidney disease, and initial creatinine clearance < 30 ml\/min. Patients were matched on Charlson Comorbidity Index, initial creatinine clearance, hypotension exposure, various nephrotoxic drug exposures, history of diabetes, heart failure, and hypertension.\n <\/jats:p>\n <\/jats:sec>\n \n Measurements and Main results<\/jats:title>\n \n AKI<\/jats:styled-content>\n occurred in 265 patients at similar rates for both groups (\n PTZ<\/jats:styled-content>\n 11.4% vs\n SAM<\/jats:styled-content>\n 9.2%; p=0.14). After stratifying by vancomycin exposure and controlling for confounders, there was no difference in the risk of\n AKI<\/jats:styled-content>\n for\n SAM<\/jats:styled-content>\n or\n PTZ<\/jats:styled-content>\n (adjusted odds ratio [aOR] 0.87, 95% confidence interval [CI] 0.59\u20131.25). The addition of vancomycin (VAN) to\n PTZ<\/jats:styled-content>\n increased the likelihood of\n AKI<\/jats:styled-content>\n compared with\n PTZ<\/jats:styled-content>\n alone (a\n OR<\/jats:styled-content>\n 1.77, 95%\n CI<\/jats:styled-content>\n 1.26\u20132.46). Concomitant\n SAM<\/jats:styled-content>\n and\n VAN<\/jats:styled-content>\n therapy was not associated with a significant increase in\n AKI<\/jats:styled-content>\n compared with\n SAM<\/jats:styled-content>\n monotherapy (aOR 1.01, 95%\n CI<\/jats:styled-content>\n 0.48\u20131.97).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n Rates of\n AKI<\/jats:styled-content>\n were similar for\n PTZ<\/jats:styled-content>\n and\n SAM<\/jats:styled-content>\n in a matched cohort. The addition of a \u03b2\u2010lactamase inhibitor is not likely the mechanism in the observed increased rates of\n AKI<\/jats:styled-content>\n in patients treated with vancomycin and\n PTZ<\/jats:styled-content>\n .\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/phar.1918","type":"journal-article","created":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T01:57:07Z","timestamp":1488333427000},"page":"593-598","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Acute Kidney Injury in Patients Treated with\n IV<\/scp>\n Beta\u2010Lactam\/Beta\u2010Lactamase Inhibitor Combinations"],"prefix":"10.1002","volume":"37","author":[{"given":"W. Cliff","family":"Rutter","sequence":"first","affiliation":[{"name":"University of Kentucky College of Pharmacy Lexington Kentucky"},{"name":"University of Kentucky HealthCare Lexington Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Burgess","sequence":"additional","affiliation":[{"name":"University of Kentucky College of Pharmacy Lexington Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,4,20]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1442"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03011-15"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.2146\/sp150007"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1428"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1738"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12410"},{"key":"e_1_2_6_8_1","article-title":"Top guns: the \u201cMaverick\u201d and \u201cGoose\u201d of empiric therapy","author":"Davies SW","year":"2015","journal-title":"Surg Infect"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-015-1518-9"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/cc2872"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.31.7.658"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq433"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/pan\/mpl013"},{"key":"e_1_2_6_14_1","unstructured":"R: A language and environment for statistical computing. [Internet]. R Foundation for Statistical Computing 2014. Available fromhttp:\/\/www.R-project.org. Accessed April 1 2016."},{"key":"e_1_2_6_15_1","unstructured":"RStudio Team.RStudio: Integrated Development for R[Internet].Boston MA 2015. Available fromhttp:\/\/www.rstudio.com\/. Accessed April 1 2016."},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2008.04.002"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn128"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1918","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1918","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:44:25Z","timestamp":1761068665000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,20]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1002\/phar.1918"],"URL":"https:\/\/doi.org\/10.1002\/phar.1918","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,20]]},"assertion":[{"value":"2017-04-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}